Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors

详细信息    查看全文

• 作者：Li Tan^a ; ^b ; ^j ; Deepak Gurbani^c ; ^j ; Ellen L. Weisberg^e ; ^f ; ^j ; Douglas S. Jones^g ; ^h ; ^j ; Suman Rao^a ; ^b ; ^g ; William D. Singer^c ; ^d ; Faviola M. Bernard^c ; ^d ; Samar Mowafy^a ; ^b ; ⁱ ; Annie Jenney^g ; Guangyan Du^a ; ^b ; Atsushi Nonami^e ; ^f ; James D. Griffin^e ; ^f ; Douglas A. Lauffenburger^h ; Kenneth D. Westover^c ; ^d ; ^{Kenneth.Westover@UTSouthwestern.edu} ; Peter K. Sorger^g ; ^{Peter_Sorger@hms.harvard.edu} ; Nathanael S. Gray^a ; ^b ; ^{Nathanael_Gray@dfci.harvard.edu}
• 关键词：TAK1 ; Polypharmacology ; Multitarget ; Cancer ; Cytokine secretion
• 刊名：Bioorganic & Medicinal Chemistry
• 出版年：2017
• 出版时间：15 February 2017
• 年：2017
• 卷：25
• 期：4
• 页码：1320-1328
• 全文大小：1701 K
• 卷排序：25

文摘

Targeted polypharmacology provides an efficient method of treating diseases such as cancer with complex, multigenic causes provided that compounds with advantageous activity profiles can be discovered. Novel covalent TAK1 inhibitors were validated in cellular contexts for their ability to inhibit the TAK1 kinase and for their polypharmacology. Several inhibitors phenocopied reported TAK1 inhibitor 5Z-7-oxozaenol with comparable efficacy and complementary kinase selectivity profiles. Compound 5 exhibited the greatest potency in RAS-mutated and wild-type RAS cell lines from various cancer types. A biotinylated derivative of 5, 27, was used to verify TAK1 binding in cells. The newly described inhibitors constitute useful tools for further development of multi-targeting TAK1-centered inhibitors for cancer and other diseases.